Vitality Biopharma of California has developed a new class of cannabis-derived cannabinoid prodrugs, known as cannabosides, which can enable the selective delivery of cannabidiol (CBD), a cannabinoid compound, to the intestinal tract, and reduce the delivery of the psychoactive tetrahydrocannabinol (THC) to the brain. Vitality Biopharma, which is developing cannabinoid prodrug pharmaceuticals to treat neurological and inflammatory disorders, has released an update on its clinical development roadmap, which includes cannabosides for the treatment of inflammatory bowel disease (IBD). The company, formerly known as Stevia First Corp, changed its name to Vitality Biopharma, Inc., in June with the goal of developing these pharmaceuticals. Vitality explains that prodrugs are medications or compounds that are metabolized (i.e., converted within the body) into a pharmacologically active drug, often to improve bioavailability when a drug itself is poorly absorbed, or to address other issues that make particular molecules with therapeutic potential unappealing as candidates for future product development. A prodrug may also be used to selectively target a specific tissue or organ, such as the brain or gut, enabling the drug to have effect in that organ.